Briefings in Bioinformatics,
Год журнала:
2024,
Номер
26(1)
Опубликована: Ноя. 22, 2024
Abstract
The
unique
cyclic
structure
of
peptides
grants
them
remarkable
stability
and
bioactivity,
making
powerful
candidates
for
treating
various
diseases.
However,
the
lack
standardized
tools
peptide
data
has
hindered
their
potential
in
today’s
artificial
intelligence–driven
efficient
drug
design
landscape.
To
bridge
this
gap,
here
we
introduce
a
Python
package
named
cyclicpeptide
specifically
design.
This
provides
such
as
Structure2Sequence,
Sequence2Structure,
format
transformation
to
process,
convert,
standardize
sequence
data.
Additionally,
it
includes
GraphAlignment
peptide–specific
alignment
search
PropertyAnalysis
enhance
understanding
drug-like
properties
applications.
comprehensive
suite
aims
streamline
integration
into
modern
discovery
pipelines,
accelerating
development
peptide–based
therapeutics.
Pharmaceutics,
Год журнала:
2023,
Номер
15(7), С. 1916 - 1916
Опубликована: Июль 10, 2023
Artificial
intelligence
(AI)
has
emerged
as
a
powerful
tool
that
harnesses
anthropomorphic
knowledge
and
provides
expedited
solutions
to
complex
challenges.
Remarkable
advancements
in
AI
technology
machine
learning
present
transformative
opportunity
the
drug
discovery,
formulation,
testing
of
pharmaceutical
dosage
forms.
By
utilizing
algorithms
analyze
extensive
biological
data,
including
genomics
proteomics,
researchers
can
identify
disease-associated
targets
predict
their
interactions
with
potential
candidates.
This
enables
more
efficient
targeted
approach
thereby
increasing
likelihood
successful
approvals.
Furthermore,
contribute
reducing
development
costs
by
optimizing
research
processes.
Machine
assist
experimental
design
pharmacokinetics
toxicity
capability
prioritization
optimization
lead
compounds,
need
for
costly
animal
testing.
Personalized
medicine
approaches
be
facilitated
through
real-world
patient
leading
effective
treatment
outcomes
improved
adherence.
comprehensive
review
explores
wide-ranging
applications
delivery
form
designs,
process
optimization,
testing,
pharmacokinetics/pharmacodynamics
(PK/PD)
studies.
an
overview
various
AI-based
utilized
technology,
highlighting
benefits
drawbacks.
Nevertheless,
continued
investment
exploration
industry
offer
exciting
prospects
enhancing
processes
care.
Trends in Sciences,
Год журнала:
2024,
Номер
21(8), С. 8287 - 8287
Опубликована: Июнь 1, 2024
The
spread
of
infectious
diseases
such
as
COVID-19
depends
on
complex
fluid
dynamics
interactions
between
pathogens
and
phases,
including
individual
droplets
multiphase
clouds.
Understanding
these
is
crucial
for
predicting
controlling
disease
spread.
This
applies
to
human
animal
exhalations,
coughs
sneezes,
well
bursting
bubbles
that
create
micron-sized
in
various
indoor
outdoor
environments.
By
exploring
case
studies
this
regard,
study
examines
the
emerging
field
transmission,
focusing
flows,
interfacial
turbulence,
pathogens,
traffic,
aerosol
ventilation,
breathing
microenvironments.
These
results
indicate
increased
ventilation
rates
local
methods
can
effectively
reduce
concentration
SARS-CoV-2-laden
aerosols
immediate
spaces
individuals.
In
a
displacement-ventilated
room,
both
neutral
unstable
conditions
were
more
effective
removing
breathed
from
air,
regardless
presence
test
subjects.
However,
stable
may
increase
risk
infection
individuals
living
confined
spaces.
Thus,
findings
are
useful
providing
practical
guidance
managing
airborne
infections.
HIGHLIGHTS
Fluid
affect
transmission
explored
flow,
dispersion,
respiratory
zones
Increased
SARS-CoV-2
Displacement
eliminates
under
Cramped
damp
environments
GRAPHICAL
ABSTRACT
Advanced Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 18, 2025
Abstract
Inspired
by
nature's
ability
to
master
materials
for
performance
and
sustainability,
biomimicry
has
enabled
the
creation
of
bioinspired
structural
color,
superadhesion,
hydrophobicity
hydrophilicity,
among
many
others.
This
review
summarizes
emerging
trends
in
novel
sustainable
fluorocarbon‐free
designs
creating
superhydrophobic
superoleophobic
surfaces.
It
discusses
methods,
challenges,
future
directions,
alongside
impact
computational
modeling
artificial
intelligence
accelerating
experimental
development
more
surface
materials.
While
significant
progress
is
made
materials,
surfaces
remain
a
challenge.
However,
bioinspiration
techniques
supported
platforms
are
paving
way
new
renewable
biodegradable
repellent
that
meet
environmental
standards
without
sacrificing
performance.
Nevertheless,
despite
concerns,
policies,
several
still
continue
apply
fluorination
other
environmentally
harmful
achieve
required
standard
repellency.
As
discussed
this
critical
review,
paradigm
integrates
advanced
characterization,
nanotechnology,
additive
manufacturing,
modeling,
coming,
generate
with
tailored
superhydrophobicity
superoleophobicity
while
adhering
standards.
Advanced Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 10, 2024
Abstract
The
pioneering
work
on
liposomes
in
the
1960s
and
subsequent
research
controlled
drug
release
systems
significantly
advances
development
of
nanocarriers
(NCs)
for
delivery.
This
field
is
evolved
to
include
a
diverse
array
such
as
liposomes,
polymeric
nanoparticles,
dendrimers,
more,
each
tailored
specific
therapeutic
applications.
Despite
significant
achievements,
clinical
translation
limited,
primarily
due
low
efficiency
delivery
an
incomplete
understanding
nanocarrier
interactions
with
biological
systems.
Addressing
these
challenges
requires
interdisciplinary
collaboration
deep
nano‐bio
interface.
To
enhance
design,
scientists
employ
both
physics‐based
data‐driven
models.
Physics‐based
models
provide
detailed
insights
into
chemical
reactions
at
atomic
molecular
scales,
while
leverage
machine
learning
analyze
large
datasets
uncover
hidden
mechanisms.
integration
presents
harmonizing
different
modeling
approaches
ensuring
model
validation
generalization
across
However,
this
crucial
developing
effective
targeted
By
integrating
enhanced
data
infrastructure,
explainable
AI,
computational
advances,
potentials,
researchers
can
develop
innovative
nanomedicine
solutions,
ultimately
improving
outcomes.
Advances in Colloid and Interface Science,
Год журнала:
2024,
Номер
329, С. 103200 - 103200
Опубликована: Май 21, 2024
Age-related
macular
degeneration
(AMD)
is
a
leading
cause
of
vision
loss
in
the
elderly.
The
current
standard
treatment
for
AMD
involves
frequent
intravitreal
administrations
therapeutic
agents.
While
effective,
this
approach
presents
challenges,
including
patient
discomfort,
inconvenience,
and
risk
adverse
complications.
Nanoparticle-based
drug
delivery
platforms
offer
promising
solution
to
overcome
these
limitations.
These
are
engineered
target
retina
specifically
control
release,
which
enhances
retention,
improves
concentration
bioavailability
at
retinal
site,
reduces
frequency
injections.
This
review
aims
uncover
design
principles
guiding
development
highly
effective
nanoparticle-based
treatment.
By
gaining
deeper
understanding
physiology
ocular
barriers
physicochemical
properties
nanoparticles,
we
establish
basis
designing
nanoparticles
optimize
retention
retina.
Furthermore,
recent
strategies
highlight
their
potential
improving
efficiency.
Lastly,
address
challenges
opportunities
field,
providing
insights
into
future
improve
outcomes
patients.
Clinical Pharmacology & Therapeutics,
Год журнала:
2024,
Номер
115(6), С. 1212 - 1232
Опубликована: Март 7, 2024
Adeno-associated
virus
(AAV)
vector-based
gene
therapy
is
an
innovative
modality
being
increasingly
investigated
to
treat
diseases
by
modifying
or
replacing
defective
genes
expressing
therapeutic
entities.
With
its
unique
anatomic
and
physiological
characteristics,
the
eye
constitutes
a
very
attractive
target
for
therapy.
Specifically,
ocular
space
easily
accessible
generally
considered
"immune-privileged"
with
low
risk
of
systemic
side
effects
following
local
drug
administration.
As
retina
cells
have
limited
cellular
turnover,
one-time
delivery
has
potential
provide
long-term
transgene
expression.
Despite
initial
success
voretigene
neparvovec
(Luxturna),
first
approved
therapy,
there
are
still
challenges
be
overcome
successful
clinical
development
these
products
scientific
questions
answered.
The
current
review
paper
aims
integrate
published
experience
learned
thus
far
AAV-based
related
preclinical
translation;
first-in-human
dose
selection;
relevant
bioanalytical
assays
strategies;
considerations
including
trial
design,
biodistribution
vector
shedding,
immunogenicity,
expression,
pediatric
populations;
opportunities
model-informed
development;
regulatory
perspectives.
information
presented
herein
intended
serve
as
guide
inform
strategy
focus
on
pharmacology.